Evidence

References

Period Problems AND Effective treatment for fertility issues 70%

Papaleo E, Unfer V et al, Myo-inositol in patients with polycystic ovary syndrome – a novel method for ovulation induction Gynec Endoc December 2007; 23(12): 700–703

Costantino D et al, Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharm Sci 2009; 13: 105-110

Maintaining a healthy pregnancy: Reduces the risk of developing diabetes in pregnancy by 65%:

Matarrelli B, Vitacolonna E et al, Effect of myo-inositol in pregnancy of maternal gestational DM and foetal outcomes – Randomised Study. J Matern Fetal Neonatal Med, 2013; 26(10): 967-972

D’Anna R et al, Myo-Inositol Supplementation and Onset of Gestational Diabetes Mellitus in Pregnant Women With a Family History of Type 2 Diabetes – a prospective, randomized, placebo-controlled study.

Diabetes Care, Vol 36, April 2013: 854-857

D’anna et al., Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women. Obstetrics and Gynecology, Vol. 126, no. 2, August 2015; 310 – 315

Effective treatment for unwanted hair

Zacchè et al, Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocr Aug 2009; 25(8): 508-513

Acne and skin problems

Zacchè et al, Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocr Aug 2009; 25(8): 508-513

Weight Problems: 6% weight loss over 6 months

Capasso I, Esposito E et al, Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials 2013, 14:273


A. Genazzani AD et al, Differential insulin response to myo-inositol administration in obese PCOS patients., Gyecol Endocr, 2012; 28(12):969-973

B. Santamaria A et al, One year effects of myo-inositol in postmenopausal women with metabolic syndrome. Climacteric 2012; 15: 490-495

C. Giugliano E et al, The prevention of gestational diabetes. J Diabetes Metab 2013, 4:286

D. Gerli S, Papaleo E et al, Randomized, double blind placebo-controlled trial effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med & Pharm Sci 2007; 11: 347-354

E. Artini P, Di Berardino O et al, Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome – A randomised study optimised. Gynec Endoc, 2013; 29(4): 375-379

F. Colazingari S, Treglia M et al, The combined therapy Myo-inositol plus D-chiro-Inositol rather than D-chiro-inositol is able to improve IVF outcomes – results from a randomised controlled trial. Arch Gynecol Obstet (2013) 288:1405-1411

G. Carlomagno G, Unfer V, Inositol safety – clinical evidences. Eur Rev Med & Pharm Sci 2011; 15: 931-936

H. Unfer V, Carlomagno G et al, Effects of myo-inositol in women with PCOS – a systematic review of randomized controlled trials. Gyn Endoc, 2012; 1–7

I. Diamanti-Kandarakis E, Dunaif A, Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocrine Reviews 33: 981–1030, 2012

J. Donà G, Sabbadin C et al, Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J of Endoc (2012) 166 703–710

K. Ciotta L, Stracquadanio M et al, Effects of Myo-Inositol supplementation on oocytes quality in PCOS patients a double blind trial. Eur Rev Med & Pharm Sci 2011; 15: 509-514

L. Franks S, Gilling-Smith C et al, Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am. 1999 Jun;28(2):361-78

M. Nestler J, Strauss J, Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am. 1991 Dec;20(4):807-23

N. International Diabetes Federation, 2005

O.Essah P, Wickham E, Nestler J, The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol. 2007 Mar;50(1):205-25